University of British Columbia

Angiotech International Ag

Centre for Drug Research and Development

Angiotech Pharmaceuticals, Inc.

Cdrd Ventures Inc.

Richard Tom Liggins

Dechi Guan

William L Hunter

Martin E Gleave

David M Gravett

Rajesh Kumar Kainthan

John K Jackson

Jayachandran N Kizhakkedathu

Donald Elliott Brooks

Philip Michael Toleikis

Helen M Burt

Clement Mugabe

Troy A E Loss

Tom Han Hsiao Hsieh

Rui Avelar

Lu Ye

Alan So

Arpita Maiti

Stephen Paul Arns

Davy Jérémy Baudelet

Eric Roy Simonson

Pierre E Signore

Brian G Amsden

James Brian Jaquith

Nag Sharwan Kumar

The present invention is directed to somatostatin receptor antagonist compounds having the structure of Formula I, compositions comprising the same, and methods of using such compounds and compositions. The compounds may be useful in the prevention or treatment of hypoglycemia. 

Somatostatin receptor antagonist compounds and methods of using the same

Herein are provided derivatized hyperbranched polyglycerols ('dHPGs'). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with CCalkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.

Derivatized hyperbranched polyglycerols

Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.

Compositions and methods for coating medical implants

Medical implants are provided which release a fluoropyrimidine or an analog thereof, thereby inhibiting or reducing the incidence of infection associated with the implant.

Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.

Medical implants and fibrosis-inducing agents

A process for forming microspheres that includes passing a first composition containing polymer and solvent through an orifice and directly into a second composition containing water and a microsphere-stabilizing agent, under at least one of conditions (a) and (b), wherein (a) the first composition flows through a first conduit along a first path and exits the first conduit at the orifice, the second composition flows through a second conduit along a second path in an upstream to downstream direction, the first conduit is connected to the second conduit and terminates at the orifice, the first and second paths being orientated at an angle &thgr; relative to each other, wherein 0&deg;<&thgr;<180&deg;; (b) the first composition being at a first temperature and including a solvent having a boiling point, the second composition being at a second temperature, the boiling point of the solvent being less than the second temperature; and forming a composition including water and microspheres, the microspheres being formed, at least in part, by the polymer. Such microspheres are suitable for use in the delivery of bioactive agents for animal, aquarian and human use, as a means of radio-imaging tissue, as well as for the controlled release of agro-chemicals.

Methods for microsphere production

Growing community of inventors

Coquitlam, Canada

Richard Tom Liggins